SMILE: Strategy for Maintenance of HIV suppression with once daiLy Integrase inhibitor+darunavir/ritonavir in children (PENTA 17) - A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to once daily integrase inhibitor administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants. - PENTA 17 - SMILE

Fondazione PENTA ONLUS0 个研究点目标入组 300 人开始时间: 2017年10月20日最近更新: 2021年4月5日

研究概览

暂无简介。

•1.HIV-1 infected children aged =12 years old and weighting = 40kg* at the screening visit.
•2.Aged 6 to < 18 years old**.
•3.Parents or guardians, and children where appropriate, willing and able to give informed consent and to adhere to the protocol.
•4.Children must have all HIV-1 RNA viral loads <50c/mL for at least 12
•months with a minimum of two separate results before screening.
•5.Children on a 3-drug PI/r or NNRTI containing regimen for at least 24 weeks.
•6.Children/parents/guardians prepared to switch if randomised to INSTI+ darunavir/ritonavir arm.
•7.Children and parents prepared to restart the current ART regimen
•after simplification if viral load restart criteria are met.
•8.Be affiliated or beneficiary to Health Social security scheme (in
•countries where this is mandatory).
•*. Initially, enrolment will be of participants = 12 years old and =40kg
•**. As more data become available on younger children, a protocol
•amendment is planned to include younger children and/or lower weight bands.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 300
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.Receiving or requiring agents with interactions with DRV, RTV, or any once daily integrase inhibitor
•2.Evidence of resistance to DRV or integrase inhibitors
•3.Previous exposure to integrase inhibitors for more than 2 weeks
•4.Intercurrent illness
•5.Creatinine =1.8ULN or ALT =5ULN or ALT = 3ULN and bilirubin =
•2ULN at screening
•6.Patients with severe hepatic impairment or unstable liver disease
•known biliary abnormalities
•7.Diagnosis of tuberculosis and on anti-tuberculosis treatment
•8.Hepatitis B or Hepatitis C co-infection
•9.Pregnancy or risk of pregnancy in girls of child-bearing potential
•unless committed to taking effective contraception
•10. History or presence of known allergy or some other contraindication to the study drugs or their components as described in the SmPC

发起方